Cardiolipin and Barth Syndrome

The composition and dynamics of the mitochondrial complexome
Ulrich Brandt, PhD, Radboud University Medical Center, Nijmegen, The Netherlands

Mechanisms underlying TCA cycle defects in tafazzin deficient cells – Potential new targets for treatment of Barth syndrome
Miriam L. Greenberg, PhD, Wayne State University, Detroit, MI

2 Poster Presenters:

Poster Presentation 1
Aberrant cardiolipin metabolism is associated with cognitive deficiency and hippocampal alteration in tafazzin knockdown mice
Grant M. Hatch, PhD, Professor, Departments of Pharmacology & Therapeutics and Biochemistry & Medical Genetics, University of Manitoba, Winnipeg, Canada

Poster Presentation 2
Investigation into clinical, metabolic and molecular factors in Barth syndrome
Arianna F. Anzmann, John Hopkins School of Medicine, Baltimore, MD

Targeting ALCAT1 for the treatment of Barth syndrome  
Yuguang Shi, PhD, University of Texas Health Sciences Center, San Antonio, TX

Biophysical approaches toward understanding the molecular mechanism of action of SS-31 (Elamipretide)
Nathan Alder, PhD, University of Connecticut, Storrs, CT

The structural molecular diversity of cardiolipins
Markus Keller, PhD, Medical University Innsbruck, Innsbruck, Austria

Conference Wrap-Up

Arnold W. Strauss, MD, Cincinnati Children’s Research Foundation, Cincinnati, OH
W. Todd Cade, PT, PhD, Washington University School of Medicine, St. Louis, MO
Grant M. Hatch, PhD, University of Manitoba, Winnipeg, Canada
Michael Schlame, MD, New York University School of Medicine, New York, NY
Matthew J. Toth, PhD, Barth Syndrome Foundation